All canine diagnoses

Your dog was diagnosed with Anal Sac Apocrine Gland Adenocarcinoma. Accounts for ~2% of cutaneous/subcutaneous tumours and ~17% of perianal tumours. Paraneoplastic hypercalcaemia in 25-50% at diagnosis. High metastatic rate to sublumbar lymph nodes (50-80% at diagnosis). Compare 4 treatment options for dogs including Sacculectomy (Surgery Alone), Surgery + Adjuvant Chemotherapy, Surgery + Radiation Therapy — with survival times, costs, and what to expect during treatment.

🐕

Anal Sac Apocrine Gland Adenocarcinoma

BreedsEnglish Cocker SpanielCocker SpanielEnglish Springer SpanielCavalier King Charles SpanielGerman ShepherdDachshund
canine

Epithelial

About This Cancer

Anal sac apocrine gland adenocarcinoma arises from the specialised scent glands within the anal sacs, two small pouches located on either side of the anus. These glands normally produce a pungent, oily secretion used for territorial marking. The cancer is notable for two features: it frequently spreads early to the sublumbar (internal pelvic) lymph nodes — these are already involved in 50–80% of cases at diagnosis — and it commonly produces a protein called parathyroid hormone-related protein (PTHrP) that causes dangerously elevated blood calcium levels (hypercalcaemia) in 25–50% of affected dogs. This paraneoplastic hypercalcaemia can cause kidney damage, weakness, and loss of appetite, and is sometimes the first clinical sign that prompts investigation. Spaniel breeds appear to be at higher risk. Treatment typically involves surgical removal of the affected anal sac, often combined with chemotherapy.

Modified staging for canine ASAGAC

No universally agreed TNM staging. Commonly stratified by tumour size, lymph node status, and distant metastasis.

Stage LocalPrimary tumour confined to anal sac, no LN metastasis
Stage RegionalSublumbar lymph node metastasis present
Stage DistantDistant metastasis (pulmonary, hepatic, splenic)
Prognostic Factors(3)
Tumour sizeTumours >10 cm² have worse prognosis. Dogs with tumours >5 cm have 11-fold increased death risk.(Williams et al., 2003)
Sublumbar lymph node metastasisPresent in 50-80% at diagnosis but does not preclude treatment. Debulking/excision of LN may improve outcomes.(Williams et al., 2003)
HypercalcaemiaPreviously considered negative prognostic factor but recent data suggests it does not independently worsen prognosis when treated appropriately.(Hobbs et al., 2020)
Minimum Workup(8 steps)
1Rectal examination (mass palpation, bilateral glands)
2Abdominal ultrasound (sublumbar lymph nodes — critical for staging)
3Thoracic radiographs (3-view) for pulmonary metastasis
4Serum calcium and ionized calcium (paraneoplastic hypercalcaemia)
5Complete blood count and serum biochemistry
6Fine needle aspirate of primary mass
7FNA of enlarged sublumbar lymph nodes if accessible
8Abdominal CT for surgical planning (sublumbar LN assessment)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Sacculectomy (Surgery Alone)
~15 mo (10–20)
Surgery + Adjuvant Chemotherapy
~18 mo (12–24)
Surgery + Radiation Therapy
~28 mo (18–36)
Toceranib (Palladia) ± Surgery
~12 mo (8–18)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.